The financials
Abbott Laboratories by the numbers
Abbott Laboratories (ABT) reported revenue of $11.2B in Q1 2026 (quarter ended March 31, 2026), up 7.8% from the same quarter a year earlier. That came with a gross margin of 56% and net income of $1.08B (9.6% of revenue). For the full year FY2025, revenue was $44.3B (+5.7% year on year) and net income $6.52B. Its largest segment in 2026-Q2 was Nutritional Products at $525M, 41% of the disclosed total, just ahead of Diagnostic Products at 29%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $11.2B | $10.4B | +7.8% |
| Gross profit | $6.27B | $5.89B | +6.5% |
| Operating income | $1.34B | $1.69B | −21% |
| Net income | $1.08B | $1.32B | −19% |
| Diluted EPS | $0.61 | $0.76 | −20% |
| Operating | Revenue | Share |
|---|---|---|
| Nutritional Products | $525M | 41% |
| Diagnostic Products | $377M | 29% |
| Medical Devices | $377M | 29% |
Business Segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Q2 2026Total $1.28B (+6.9%)
Medical Devices grew +11% year on yearNutritional Products -11% year on year
Segment Latestquarter on quarteryear on year
- Nutritional Products$525.0M$525.0MQoQ +2.7%year on year -11%+2.7%-11%
- Diagnostic Products$377.0M$377.0MQoQ +8.6%year on year +7.4%+8.6%+7.4%
- Medical Devices$377.0M$377.0MQoQ +11%year on year +11%+11%+11%
- Established Pharmaceutical Products$0.00$0.00QoQ -year on year ---
Medical Devices
Ranks #16 of 35 by Smart Score